DWM
JAZZ icon

Doyle Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Doyle Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-75
Closed -$9K – 464
2018
Q4 		$9K Buy
+75
New +$11.1K ﹤0.01% 642

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Doyle Wealth Management's JAZZ Position: Q1 2019 in Review

Doyle Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 75 shares — an estimated $9K sold.

Doyle Wealth Management first reported a position in JAZZ in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • Doyle Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 75 Jazz Pharmaceuticals shares in Q1 2019, an estimated $9K.
  • Doyle Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Doyle Wealth Management's Jazz Pharmaceuticals position peaked at $9K in Q4 2018.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Doyle Wealth Management's 13F filing for Q1 2019, filed 13 May 2019.